SCHEMBL4167222

SCHEMBL4167222

O=C(O)CNC(=O)[C@@H](CS)NCC(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.51
GSTK1 Q9Y2Q3 1/20 0.51
ALDH1A1 P00352 3/20 0.50
MAPT P10636 3/20 0.50
PTGS2 P35354 2/20 0.50
LMNA P02545 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
MME P08473 7/20 0.45
ACE P12821 5/20 0.45
ECE1 P42892 2/20 0.45
BLM P54132 2/20 0.45
HPGD P15428 1/20 0.45
MAPK1 P28482 1/20 0.45
HSD17B10 Q99714 1/20 0.45
MEN1 O00255 1/20 0.45
NPEPPS P55786 1/20 0.45
KMT2A Q03164 1/20 0.45
CPA1 P15085 1/20 0.43
ACE2 Q9BYF1 1/20 0.43
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4635630 1.00 PTGS1 (0.51) PTGS1GSTK1ALDH1A1MAPTPTGS2
SCHEMBL4635618 1.00 PTGS1 (0.51) PTGS1GSTK1ALDH1A1MAPTPTGS2
SCHEMBL929620 0.90 PTGS1 (0.43) PTGS1GSTK1ALDH1A1MAPTPTGS2
SCHEMBL930399 0.86 PTGS1 (0.41) PTGS1GSTK1ALDH1A1MAPTPTGS2
SCHEMBL27639531 0.86 ALDH1A1 (0.50) PTGS1GSTK1ALDH1A1MAPTPTGS2
SCHEMBL930206 0.83 PTGS1 (0.39) PTGS1GSTK1ALDH1A1MAPTPTGS2
SCHEMBL930209 0.82 PTGS1 (0.38) PTGS1GSTK1ALDH1A1MAPTPTGS2
SCHEMBL19579377 0.82 PTGS1 (0.58) PTGS1GSTK1ALDH1A1MAPTPTGS2
SCHEMBL197221 0.80 MAPT (0.50) PTGS1GSTK1ALDH1A1MAPTPTGS2
SCHEMBL69148 0.80 MAPT (0.50) PTGS1GSTK1ALDH1A1MAPTPTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1933642-B1 SALT ENHANCING COMPOUNDS AND USE HOFMANN THOMAS FRANK (DE) 2011-12-21 EP claimed
US-20090155440-A1 Salt Enhancing Compounds and Use GIVAUDAN SA (CH) 2009-06-18 US claimed
EP-3806661-B1 USE OF ANTAGONISTS OF T2R54 FIRMENICH INCORPORATED (US) 2025-07-02 EP disclosed
EP-4566459-A2 ANTAGONISTS OF T2R54 AND COMPOSITIONS AND USES THEREOF Firmenich Incorporated (US) 2025-06-11 EP disclosed
US-12295396-B2 Antagonists of T2R54 and compositions and uses thereof FIRMENICH INCORPORATED (US) 2025-05-13 US disclosed
CN-119264123-A Antagonists of T2R54, compositions thereof and uses thereof 弗门尼舍公司 2025-01-07 CN disclosed
CN-113194742-B Antagonists of T2R54, compositions thereof and uses thereof 弗门尼舍公司 2024-09-27 CN disclosed
US-20240114942-A1 Antagonists of T2R54 and Compositions and Uses Thereof FIRMENICH INCORPORATED (US) 2024-04-11 US disclosed
US-20240108040-A1 HIGH INTENSITY SWEETENERS FIRMENICH INCORPORATED (US) 2024-04-04 US disclosed
US-11871772-B2 Antagonists of T2R54 and compositions and uses thereof FIRMENICH INCORPORATED (US) 2024-01-16 US disclosed
US-11758933-B2 High intensity sweeteners FIRMENICH INCORPORATED (US) 2023-09-19 US disclosed
US-20170119032-A1 HIGH INTENSITY SWEETENERS FIRMENICH INCORPORATED 2017-05-04 US disclosed
WO-2017075257-A2 HIGH INTENSITY SWEETENERS SENOMYX, INC. (US) 2017-05-04 WO disclosed
US-20170096418-A1 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 FIRMENICH INCORPORATED 2017-04-06 US disclosed
US-20170087199-A1 COMPOSITIONS FOR DELIVERING A COOLING SENSATION SENOMYX INC (US) 2017-03-30 US disclosed
US-20160376263-A1 BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF SENOMYX INC (US) 2016-12-29 US disclosed
EP-1933642-B1 SALT ENHANCING COMPOUNDS AND USE HOFMANN THOMAS FRANK (DE) 2011-12-21 EP disclosed
US-20090155440-A1 Salt Enhancing Compounds and Use GIVAUDAN SA (CH) 2009-06-18 US disclosed
EP-1933642-A1 SALT ENHANCING COMPOUNDS AND USE Thomas Frank Hofmann & Andreas Dunkel Inst. für Lebensmittelchemie (DE) 2008-06-25 EP disclosed
WO-2007042274-A1 SALT ENHANCING COMPOUNDS AND USE THOMAS FRANK HOFMANN & ANDREAS DUNKEL (DE) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240108040-A1 HIGH INTENSITY SWEETENERS TAS2R40, TAS2R60, TAS1R1 PTGS1 1786/4885GSTK1 3185/4885ALDH1A1 978/4885
US-20170119032-A1 HIGH INTENSITY SWEETENERS TAS2R40, TAS2R60, TAS1R1 PTGS1 1786/4885GSTK1 3185/4885ALDH1A1 978/4885
US-11871772-B2 Antagonists of T2R54 and compositions and uses thereof TAS2R50, TAS2R30, TAS2R60 PTGS1 2216/4885GSTK1 4513/4885ALDH1A1 3663/4885
US-20160376263-A1 BITTER TASTE MODIFIERS INCLUDING SUBSTITUTED 1-BENZYL-3-(1-(ISOXAZOL-4-YLMETHYL)-1H-PYRAZOL-4-YL)IMIDAZOLIDINE-2,4-DIONES AND COMPOSITIONS THEREOF TAS2R5, TAS1R1, TAS2R1 PTGS1 3306/4885GSTK1 4404/4885ALDH1A1 1490/4885
US-12295396-B2 Antagonists of T2R54 and compositions and uses thereof TAS2R50, TAS2R30, TAS2R60 PTGS1 2216/4885GSTK1 4513/4885ALDH1A1 3663/4885
US-20090155440-A1 Salt Enhancing Compounds and Use TAS1R1, TAS2R41, TAS2R40 PTGS1 2559/4885GSTK1 4236/4885ALDH1A1 2141/4885
US-20240114942-A1 Antagonists of T2R54 and Compositions and Uses Thereof TAS2R50, TAS2R30, TAS2R60 PTGS1 2216/4885GSTK1 4513/4885ALDH1A1 3663/4885
US-20170087199-A1 COMPOSITIONS FOR DELIVERING A COOLING SENSATION TRPA1, PDE6G, PDE6D PTGS1 312/4885GSTK1 1061/4885ALDH1A1 1029/4885
US-11758933-B2 High intensity sweeteners TAS2R40, TAS2R60, TAS1R1 PTGS1 1786/4885GSTK1 3185/4885ALDH1A1 978/4885
US-20170096418-A1 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 TRPM8, TRPM6, TRPM4 PTGS1 1378/4885GSTK1 1260/4885ALDH1A1 3880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.